PDS Biotechnology (NASDAQ: PDSB – Get Rating) announced its quarterly earnings data Wednesday. The company reported ($ 0.32) earnings per share for the quarter, missing the consensus estimate of ($ 0.23) by ($ 0.09), MarketWatch Earnings reports. During the same quarter of the previous year, the company earned ($ 0.14) earnings per share.
The NASDAQ PDSB is trading $ 0.73 higher on Friday, reaching $ 4.56. 552,690 shares of the hands traded, compared to its average volume of 232,316. PDS Biotechnology has a 12-month low of $ 3.47 and a 12-month high of $ 17.85. The company’s fifty-day simple moving average is $ 5.66 and its 200-day simple moving average is $ 7.26.
Several analysts recently evaluated the company. Noble Financial reissued a “buy” rating and issued a $ 22.00 price target on shares of PDS Biotechnology in a report Thursday. Zacks Investment Research cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday. StockNews.com updated PDS Biotechnology to a “selling” score in a research report on Saturday, April 9. Finally, Alliance Global Partners lowered the price target for PDS biotechnology from $ 18.00 to $ 16.00 in a research report on Friday. Two analysts rated the stock with a sell rating and six gave the stock a buy rating. According to MarketBeat.com, the company currently has an average “Buy” rating and an average target price of $ 17.00.
Several institutional investors and hedge funds have recently increased or decreased their holdings in PDSB. Renaissance Technologies LLC increased its stake in PDS Biotechnology by 49.5% during Q1. Renaissance Technologies LLC now owns 665,037 shares in the company worth $ 4,117,000 after acquiring another 220,300 shares in the last quarter. Vanguard Group Inc. increased its stake in PDS Biotechnology by 7.8% during Q1. Vanguard Group Inc. now owns 1,093,885 shares in the company worth $ 6,771,000 after acquiring an additional 79,025 shares in the last quarter. Dimensional Fund Advisors LP increased its holding in PDS Biotechnology by 99.9% during Q1. Dimensional Fund Advisors LP now owns 69,628 shares in the company valued at $ 431,000 after acquiring an additional 34,797 shares in the last quarter. BlackRock Inc. increased its stake in PDS Biotechnology by 1.0% during Q1. BlackRock Inc. now owns 435,604 shares in the company worth $ 2,697,000 after acquiring another 4,199 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in PDS Biotechnology by 78.6% during the first quarter. Oppenheimer & Co. Inc. now owns 25,000 shares in the company valued at $ 155,000 after acquiring an additional 11,000 shares in the last quarter. Hedge funds and other institutional investors own 20.94% of the company’s shares.
Company profile of PDS Biotecnologie (Get evaluation)
PDS Biotechnology Corporation, a clinical stage biopharmaceutical company, focuses on the development of multifunctional anticancer immunotherapies. Its flagship product is PDS0101 (HPV16), which is in a Phase II clinical trial providing first-line treatment for recurrent / metastatic head and neck cancer, human papillomavirus-associated malignancies, and cancer of the cervix.
Receive news and assessments for PDS biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotech PDS and related companies with MarketBeat.com’s FREE daily newsletter.